Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · June 27, 2023

Intravesical Botulinum Neurotoxin A for Overactive Bladder and/or Detrusor Overactivity Related to MS

Multiple Sclerosis (Houndmills, Basingstoke, England)


Additional Info

Disclosure statements are available on the authors' profiles:

Multiple Sclerosis (Houndmills, Basingstoke, England)
Intravesical injections of botulinum neurotoxin A to treat overactive bladder and/or detrusor overactivity related to multiple sclerosis: 5-Year continuation rate and specific risk factors for discontinuation-A study from the neuro-urology committee of the French Association of Urology
Mult. Scler. 2023 Jun 02;[EPub Ahead of Print], S Delaval, PL Dequirez, C Hentzen, M Baron, E Mille, F Tariel, B Peyronnet, MA Perrouin-Verbe, A Pierache, E Chartier-Kastler, G Capon, JN Cornu, E Castel-Lacanal, X Gamé, G Karsenty, A Ruffion, P Denys, A Even, C Joussain, G Amarenco, V Phé, X Biardeau

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading